drugset / Trial / NCT06356025

Botulinum Toxin Injection in the UES for R-CPD

NCT06356025

Phase 4 Active not recruiting 50 enrolled AZ Delta KU Leuven · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to assess the effect of botulinum toxin injection into the upper esophageal sphincter in a double blind, placebo controlled study. Investigators want to assess the effect on symptoms short term (1-20 weeks after BT injection), and long term (48 weeks after BT injection). This is a prospective double-blind randomized placebo-controlled study. Questionnaires assessing symptoms will be filled out on several occasions. At 20 weeks, a reassessment of symptoms will be done, without unblinding patients or investigator. Failures (to BT or placebo, defined as no clinical improvement or improvement less than 50%) will get the chance to receive a second procedure with active treatment (BT) in open label.

Timeline

Start
2024-09-02
Primary completion
2025-12
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 75 iu Other